# Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

> **NCT03567577** · PHASE2 · COMPLETED · sponsor: **Apeptico Forschung und Entwicklung GmbH** · enrollment: 92 (actual)

## Conditions studied

- ARDS

## Interventions

- **DRUG:** Solnatide 25 mg powder for reconstitution for solution for inhalation
- **DRUG:** 0.9% Saline Solution

## Key facts

- **NCT ID:** NCT03567577
- **Lead sponsor:** Apeptico Forschung und Entwicklung GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2024-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567577, "Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03567577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*